Skip to main content
SpringerLink
Log in

Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The emergence of multi-drug-resistant tuberculosis (MDR-TB) in the European region and the high costs (nearly €536 million) generated by the nearly 72,000 notified TB cases in the EU are the factors driving the need for development and implementation of new tools against TB. In this context, cost-effectiveness analyses applying quality-adjusted life-years (QALYs) or disability-adjusted life-years (DALYs) as outcome measures for economic evaluation of improved approaches to TB control are increasingly important. While the methodology applied to derive the effectiveness data is commonly reported, less information is given regarding the derivation of utility weights in the calculation of QALYs for TB treatment. To date, despite the particular complexities of the disease, TB health effects have not been fully measured and there is no agreement on how disutility of TB disease should be accounted for. Consequently, disutility values in published studies vary considerably, and often appear to lack empirical evidence. As the need for a solid heath-economics rationale for investment in new tools against TB grows, adequate and comprehensive methods for assessing the impairments caused by different types of TB must be developed. Focusing on the assessment of DALYs as a measure of outcome in economic evaluation, we have built an exemplary model calculation applying the original TB data for Germany as reported to the Robert Koch Institute. Our work demonstrates that the use of standard equations provided in the scientific literature probably results in an underestimation of lost DALYs compared with probabilistic techniques. Providing distributions around epidemiological averages, coupled with Monte Carlo simulation to address uncertainty, may result in more realistic values. In line with a previous recommendation by the World Health Organization, it appears worthwhile to consider this more intricate approach to providing healthcare resource allocation decisions, particularly for TB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The average QALY loss of a TB case is as follows: (QALY loss per year of TB treatment) × (6 months) + (probability of hospitalization) × (QALY loss per year of hospitalization) × (24 day) + (probability of death from TB) × (QALY loss from lost future years of life) + (QALY loss from previous TB).

References

  1. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis. 2012;16:288–96.

    Article  PubMed  Google Scholar 

  2. D’Ambrosio L, Centis R, Migliori GB. Multidrug-resistant tuberculosis. N Engl J Med. 2012;367:2154 (author reply 2155-2156).

    Article  PubMed  Google Scholar 

  3. World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: World Health Organization; 2013.

  4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2013. Stockholm: European Centre for Disease Prevention and Control; 2013.

  5. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J. 2014;43:554–65.

    Article  PubMed  Google Scholar 

  6. Mwaba P, McNerney R, Grobusch MP, O’Grady J, Bates M, Kapata N, Maeurer M, Zumla A. Achieving STOP TB Partnership goals: perspectives on develop-ment of new diagnostics, drugs and vaccines for tuberculosis. Trop Med Int Health. 2011;16:819–27.

    Article  PubMed  Google Scholar 

  7. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, Deng S, Chen M. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect. 2012;64:580–8.

    Article  PubMed  Google Scholar 

  8. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–405.

    Article  CAS  PubMed  Google Scholar 

  9. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–60.

    Article  CAS  PubMed  Google Scholar 

  10. NICE. Guide to the methods of technology appraisal. Issued: June 2008.

  11. Miller TL, McNabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS ONE. 2009;4:e5080.

    Article  PubMed  PubMed Central  Google Scholar 

  12. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2012.

  13. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.

    Article  CAS  PubMed  Google Scholar 

  14. RKI. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2011. Robert Koch-Institut, Berlin; 2013.

  15. Diel R, Rutz S, Castell S, Schaberg T. Tuberculosis: cost of illness in Germany. Eur Respir J. 2012;40:143–51.

    Article  PubMed  Google Scholar 

  16. Burden M, Bakere H. A Patient’s journey. Tuberculosis. BMJ. 2012;345:e6713.

    Article  PubMed  Google Scholar 

  17. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial support to patients receiving treatment for multi-drug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health. 2014;14:46.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tsevat J, Taylor WC, Wong JB, et al. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215–22.

    Article  CAS  PubMed  Google Scholar 

  19. Porco TC, Lewis B, Marseille E, Grinsdale J, Flood JM, Royce SE. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health. 2006;6:157.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531–7.

    Article  CAS  PubMed  Google Scholar 

  21. Holland DP, Gillian D, Sanders GD, Carol D, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179:1055–60.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Choi HW, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis. 2013;17:1328–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med. 2009;169:179–87.

    Article  PubMed  Google Scholar 

  24. Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes. 2009;7:14.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bauer M, Leavens A, Schwartzman K. A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual Life Res. 2013;22:2213–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Guo N, et al. Health state utilities in latent and active tuberculosis. Value Health. 2008;11:1154–61.

    Article  PubMed  Google Scholar 

  27. Dhingra VK, Rajpal S. Health related quality of life (HRQL) scoring in tuberculosis. Indian J Tuberc. 2003;50:99–104.

    Google Scholar 

  28. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516–28.

    Article  CAS  PubMed  Google Scholar 

  29. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med. 2006;3:e241.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Winetsky DE, Negoescu DM, DeMarchis EH, Almukhamedova O, Dooronbekova A, Pulatov D, Vezhnina N, Owens DK, Goldhaber-Fiebert JD. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Med. 2012;9:e1001348.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. The World Bank. World Development Report 1993: investing in health World Bank and Oxford University Press; 1993.

  32. Murray CJL, Lopez AD (eds). Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions (Global Burden of Disease and Injury Series). Boston (MA): Harvard School of Public Health, 1996

  33. Prüss-Üstün A, Mathers C, Corvalán C, Woodward A. Introduction and methods: assessing the environmental burden of disease at national and local levels. Geneva: World Health Organization, 2003

  34. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M, editors. National burden of disease studies: a practical guide. 2nd ed. Geneva: World Health Organization; 2001.

    Google Scholar 

  35. Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life year (DALY) [online]. Available from URL: http://www.mf.uni-lj.si/dokumenti/6b695fc9385e3e2ab8fb41ec7d34660d.pdf

  36. Grosse SD, Lollar DJ, Campbell VA, Chamie M. Disability and disability-adjusted life years: not the same. Public Health Rep. 2009;124:197–202.

    PubMed  PubMed Central  Google Scholar 

  37. Murray CJL, Lopez AD (eds). Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (Global Burden of Disease and Injury Series). Boston (MA): Harvard University Press, 1996.

  38. Murray CJL. Global burden of disease—quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ. 1994;72:495–509.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001;16:326–31.

    Article  CAS  PubMed  Google Scholar 

  41. Tan-Torres Edejer T, Baltussen R, Adam T, et al. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003.

  42. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization, 2004:1–9.

  43. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.

    Article  PubMed  Google Scholar 

  44. Salomon JA. New disability weights for the global burden of disease. Bull World Health Organ. 2010;88:879.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Choosing Interventions that are Cost-Effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva: World Health Organization; 2012 (last access 30 December 2013). http://www.who.int/choice/costs/CER_thresholds/en/index.html.

Download references

Acknowledgments and Funding Disclosures

Both authors declare no support from any organization for the submitted work; no financial relationships with any organizations that could have an interest in the submitted work in the previous 3 years; no other relationships that could appear to have influenced the submitted work.

The authors contributed equally to the conceptualization of the article, calculation and interpretation of the results, and writing and review of the manuscript. Roland Diel acts as the overall guarantor of the manuscript content.

Author information

Authors and Affiliations

  1. Institute for Epidemiology, University Medical Hospital Schleswig-Holstein, Niemannsweg 11, 24015, Kiel, Germany

    R. Diel

  2. Department of Accounting and Finance, University of Hohenheim, Stuttgart, Germany

    N. Lampenius

Authors
  1. R. Diel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Lampenius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Diel.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 413 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diel, R., Lampenius, N. Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs. PharmacoEconomics 32, 617–626 (2014). https://doi.org/10.1007/s40273-014-0159-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-014-0159-5

Keywords

Search

Navigation